Jupiter Endovascular Appoints Catalin Toma, MD, as Chief Medical Officer

Jupiter Endovascular Appoints Catalin Toma, MD, as Chief Medical Officer

Jupiter Endovascular Inc., a medical technology company developing a new class of endovascular interventions based on its proprietary Transforming Fixation (TFX) technology, today announced the appointment of renowned interventional cardiologist Catalin Toma, MD, as Chief Medical Officer. The newly created role has global scope, reflecting the company's ambitions beyond the U.S.

Dr. Toma brings extensive clinical and research experience across the structural heart and interventional landscape to his new role with Jupiter Endovascular. He serves concomitantly as Director of Interventional Cardiology for the UPMC Heart and Vascular Institute, is an Associate Professor of Medicine at the University of Pittsburgh School of Medicine, and leads the Chronic Total Occlusion Program at UPMC Presbyterian Hospital. He has served as Co-Principal Investigator for a clinical study of the company’s Vertex™ Thrombectomy System for pulmonary embolism, as well as for many other high-profile clinical trials in the interventional space, including leading pulmonary embolism systems and transcatheter heart valves. He has published extensively and holds several invention patents.